08/01/2024 - Arvinas Inc.: Arvinas Corporate Presentation – January 2024

Pioneering Today

with a different kind of medicine

Transforming Tomorrow

for patients who need us

L I S T E D

ARVN

© 2024 Arvinas. All rights reserved.

Safe harbor and forward-looking statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding our expectation of brining the first PROTACT® protein degrader to market in partnership with Pfizer; the timing for our first neuroscience PROTAC® degrader to enter the clinic; the timing of presenting Phase 3 clinical trial topline data for vepdegestrant and our plans related to commercial launch of vepdegestrant; the plans for and anticipated timings related to our planned clinical trials and/or data read outs from such trials, including second-line Phase 3 clinical trials of vepdegestrant in combination with palbociclib and potentially other CDK4/6 inhibitors, a first-line Phase 3 clinical trial of vepdegestrant in combination with a CDK4 inhibitor, our Phase 3 clinical trial for ARV-766 as a monotherapy, and our Phase 1 dose escalation trials of ARV-393 (BCL6) and ARV-102 (LRRK2); the potential for vepdegestrant as an oral best-in-classtargeted therapy and to become a backbone estrogen receptor therapy in the metastatic breast cancer space; the potential therapeutic benefits and market opportunity of our product candidates, including vepdegestrant, ARV-766, ARV-393and ARV-102; the opportunity for ARV-766 in both post- and pre-novel hormonal agent settings to potentially treat metastatic castrate-sensitive prostate cancer and metastatic castrate-resistant prostate cancer; the potential for androgen receptor (AR)-targeting PROTAC degraders to address the unmet need of patients with prostate cancer across multiple stages of disease and surpass the benefits of other AR inhibitors; the timing to receive progression free survival data for the ARV-766 dose expansion

trial; whether our BCL6 PROTAC® degrader will be a first-in-class potential therapy for Diffuse Large B-Cell Lymphoma and additional opportunities for BCL6; whether PROTAC-induced LRRK2 degradation could be a disease-modifying modality for Parkinson's Disease and Progressive Supranuclear Palsy; whether a KRAS-targeting PROTAC will provide an advance in treatment for multiple cancers; and our plans and anticipated timing of clinical starts for KRAS, G12D and other programs; our plans to reach patients with additional indications

for vepdegestrant, extend our pipeline and reach profitability.

The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we and Pfizer will be able to successfully conduct clinical development for vepdegestrant (ARV-471) and receive results from our clinical trials on our expected timelines, or at all; whether we will be able to successfully conduct and complete development for our other product candidates, including whether we initiate and complete clinical trials for our product candidates and receive results from our clinical trials on our expected timelines, or at all; our ability to protect our intellectual property portfolio; whether our cash and cash equivalent resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, discussed in the "Risk Factors" section of our quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this presentation reflect our current views as of the date of this presentation with respect to future events, and we assume no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

The Arvinas name and logo are our trademarks. We also own the service mark and the registered U.S. trademark for PROTAC®. The trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. We have omitted the ® and ™ designations, as applicable, for the trademarks named in this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data

involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This presentation is intended for the investor community only. It is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Cross-trial comparisons are not based on head-to-head studies and no direct comparisons can be made.

2

Arvinas: Advancing a new therapeutic modality to patients

3

PROTAC® protein degraders combine the benefits of small molecules and gene-based knockdown technologies

4

A History of Pioneering

To transform the treatments of tomorrow

The agents mentioned above are currently under investigation; their safety and effectiveness have not yet been established

IND, investigation new drug application; CTA, clinical trial authorization

5

Arvinas' strategy positions us for the next stage of growth

7

CLINICAL PROGRAMS

Vepdegestrant

Vepdegestrant (ARV-471):First-in-class estrogen receptor (ER)-degrading PROTAC® in advanced breast cancer

Our Phase 3 VERITAC-2 monotherapy trial in the 2L+ setting is on track for topline data in 2H24

Two ongoing monotherapy trials:

• VERITAC-2:Phase 3 trial
• VERITAC: Phase 2 trial (enrollment complete, N=71)
• • At RP3D (200mg), vepdegestrant showed favorable safety profile, with <6% Grade 3+ TRAEs, no dose reductions, and low rate of discontinuations

VERITAC Phase 2 subset analysis:

• In the 8 patients in VERITAC who would meet the eligibility criteria for the Phase 3 VERITAC-2 trial (no prior fulvestrant, no prior chemotherapy for locally advanced/metastatic disease)a:
• • CBR: 62.5% (5 of 8 patients)
  • mPFS: 19 months (4 of 8 events)
  • ORR: 29% (7 evaluable patients, 2 confirmed responses)

Study design for Phase 3 VERITAC-2

(Enrolling, NCT05654623)

ESR1, estrogen receptor 1; CDK, cyclin-dependent kinase